No Data
LUYE PHARMA (02186.HK) intends to hold a Board of Directors meeting on March 28 to approve the annual performance.
GLONGHUI reported on March 14 that LUYE PHARMA (02186.HK) announced that the Board of Directors will hold a meeting on March 28, 2025 (Friday) to approve the performance results of the company and its subsidiaries for the fiscal year ending December 31, 2024, and to consider the distribution of a final dividend (if any).
Luye Pharma Group Schedules Board Meeting to Approve Annual Results and Dividend
LUYE PHARMA: NOTICE OF BOARD MEETING
AI and policy are driving forces! Hong Kong pharmaceutical stocks collectively "rebound" with WUXI BIO surging over 14% to lead the Industry.
① What technological breakthroughs have driven the improvement of research and development efficiency in the Biomedical Industry? ② What are the reasons for the leading increase in WuXi's affiliated companies?
Hong Kong stocks are experiencing fluctuations | CRO Concept stocks are warming up. The integration of AI and CXO has entered a new stage. Institutions claim that the external environment for CRO may be improving.
As of the time of writing, the CRO Concept has warmed up, with VIVA BIOTECH (01873) rising by 11.89% to 1.6 HKD; WUXI BIO (02269) increasing by 10.3% to 25.7 HKD; PHARMARON (03759) up by 5.67% to 16.04 HKD; and TIGERMED (03347) climbing by 5.86% to 37.05 HKD.
Luye Pharma Upgraded to Neutral From Sell at Goldman Sachs
